---
document_datetime: 2025-06-11 11:22:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dexdor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dexdor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1530538
conversion_datetime: 2025-12-27 20:11:45.160793
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dexdor

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 05/06/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000268932   | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update RMP to add category 3 study as additional PhV measure as requested in the outcome of PAM-LEG 016.7 - EMEA/H/C/002268/LEG/016.7 AR. Additionally, in line with EMEA/H/C/PSUSA/00000998/202403 outcome, MAH took the opportunity to update the EU RMP to remove the following issues from the summary of safety concerns : • Cortisol suppression • Convulsions • Hypothermia Minor editorial changes have been done to the RMP as well.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|